Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human umbilical cord-derived mesenchymal stem cells (Second Affiliated Hospital, School of Medicine, Zhejiang University)
- Development stage
- Unknown
- Lead developer
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
hUC-MSCs (Second Affiliated Hospital, School of Medicine, Zhejiang University) is an investigational cell therapy product consisting of human umbilical cord-derived mesenchymal stem cells. Developed by the Second Affiliated Hospital, School of Medicine, Zhejiang University and manufactured by S-Evans Biosciences, this therapy is being evaluated for the treatment of acute lung injury (ALI). The mesenchymal stem cells are believed to exert therapeutic effects through immunomodulatory and anti-inflammatory mechanisms, including the inhibition of pro-inflammatory cytokines and the modulation of immune cell responses to reduce lung inflammation and promote tissue repair. The therapy is administered via intravenous infusion and is currently being studied in prospective clinical trials to assess its safety and efficacy in patients with ALI.
- Other names
- human derived umbilical cord derived mesenchymal stem cells
Beyond the preview
Go deeper on human umbilical cord-derived mesenchymal stem cells (Second Affiliated Hospital, School of Medicine, Zhejiang University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human umbilical cord-derived mesenchymal stem cells (Second Affiliated Hospital, School of Medicine, Zhejiang University).